Cargando…

Oral iron supplements for children in malaria‐endemic areas

BACKGROUND: Iron‐deficiency anaemia is common during childhood. Iron administration has been claimed to increase the risk of malaria. OBJECTIVES: To evaluate the effects and safety of iron supplementation, with or without folic acid, in children living in areas with hyperendemic or holoendemic malar...

Descripción completa

Detalles Bibliográficos
Autores principales: Neuberger, Ami, Okebe, Joseph, Yahav, Dafna, Paul, Mical
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2016
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916933/
https://www.ncbi.nlm.nih.gov/pubmed/26921618
http://dx.doi.org/10.1002/14651858.CD006589.pub4
_version_ 1782438893103087616
author Neuberger, Ami
Okebe, Joseph
Yahav, Dafna
Paul, Mical
author_facet Neuberger, Ami
Okebe, Joseph
Yahav, Dafna
Paul, Mical
author_sort Neuberger, Ami
collection PubMed
description BACKGROUND: Iron‐deficiency anaemia is common during childhood. Iron administration has been claimed to increase the risk of malaria. OBJECTIVES: To evaluate the effects and safety of iron supplementation, with or without folic acid, in children living in areas with hyperendemic or holoendemic malaria transmission. SEARCH METHODS: We searched the Cochrane Infectious Diseases Group Specialized Register; the Cochrane Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library, MEDLINE (up to August 2015) and LILACS (up to February 2015). We also checked the metaRegister of Controlled Trials (mRCT) and World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) up to February 2015. We contacted the primary investigators of all included trials, ongoing trials, and those awaiting assessment to ask for unpublished data and further trials. We scanned references of included trials, pertinent reviews, and previous meta‐analyses for additional references. SELECTION CRITERIA: We included individually randomized controlled trials (RCTs) and cluster RCTs conducted in hyperendemic and holoendemic malaria regions or that reported on any malaria‐related outcomes that included children younger than 18 years of age. We included trials that compared orally administered iron, iron with folic acid, and iron with antimalarial treatment versus placebo or no treatment. We included trials of iron supplementation or fortification interventions if they provided at least 80% of the Recommended Dietary Allowance (RDA) for prevention of anaemia by age. Antihelminthics could be administered to either group, and micronutrients had to be administered equally to both groups. DATA COLLECTION AND ANALYSIS: The primary outcomes were clinical malaria, severe malaria, and death from any cause. We assessed the risk of bias in included trials with domain‐based evaluation and assessed the quality of the evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. We performed a fixed‐effect meta‐analysis for all outcomes and random‐effects meta‐analysis for hematological outcomes, and adjusted analyses for cluster RCTs. We based the subgroup analyses for anaemia at baseline, age, and malaria prevention or management services on trial‐level data. MAIN RESULTS: Thirty‐five trials (31,955 children) met the inclusion criteria. Overall, iron does not cause an excess of clinical malaria (risk ratio (RR) 0.93, 95% confidence intervals (CI) 0.87 to 1.00; 14 trials, 7168 children, high quality evidence). Iron probably does not cause an excess of clinical malaria in both populations where anaemia is common and those in which anaemia is uncommon. In areas where there are prevention and management services for malaria, iron (with or without folic acid) may reduce clinical malaria (RR 0.91, 95% CI 0.84 to 0.97; seven trials, 5586 participants, low quality evidence), while in areas where such services are unavailable, iron (with or without folic acid) may increase the incidence of malaria, although the lower CIs indicate no difference (RR 1.16, 95% CI 1.02 to 1.31; nine trials, 19,086 participants, low quality evidence). Iron supplementation does not cause an excess of severe malaria (RR 0.90, 95% CI 0.81 to 0.98; 6 trials, 3421 children, high quality evidence). We did not observe any differences for deaths (control event rate 1%, low quality evidence). Iron and antimalarial treatment reduced clinical malaria (RR 0.54, 95% CI 0.43 to 0.67; three trials, 728 children, high quality evidence). Overall, iron resulted in fewer anaemic children at follow up, and the end average change in haemoglobin from base line was higher with iron. AUTHORS' CONCLUSIONS: Iron treatment does not increase the risk of clinical malaria when regular malaria prevention or management services are provided. Where resources are limited, iron can be administered without screening for anaemia or for iron deficiency, as long as malaria prevention or management services are provided efficiently. 12 April 2019 No update planned Other There is high‐certainty evidence that oral iron supplements do not adversely affect children living in malaria‐endemic areas, meaning further research is unlikely to change our confidence in the estimate of effect. All eligible published studies found in the last search (30 Aug, 2015) were included.
format Online
Article
Text
id pubmed-4916933
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher John Wiley & Sons, Ltd
record_format MEDLINE/PubMed
spelling pubmed-49169332016-06-22 Oral iron supplements for children in malaria‐endemic areas Neuberger, Ami Okebe, Joseph Yahav, Dafna Paul, Mical Cochrane Database Syst Rev BACKGROUND: Iron‐deficiency anaemia is common during childhood. Iron administration has been claimed to increase the risk of malaria. OBJECTIVES: To evaluate the effects and safety of iron supplementation, with or without folic acid, in children living in areas with hyperendemic or holoendemic malaria transmission. SEARCH METHODS: We searched the Cochrane Infectious Diseases Group Specialized Register; the Cochrane Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library, MEDLINE (up to August 2015) and LILACS (up to February 2015). We also checked the metaRegister of Controlled Trials (mRCT) and World Health Organization International Clinical Trials Registry Platform (WHO ICTRP) up to February 2015. We contacted the primary investigators of all included trials, ongoing trials, and those awaiting assessment to ask for unpublished data and further trials. We scanned references of included trials, pertinent reviews, and previous meta‐analyses for additional references. SELECTION CRITERIA: We included individually randomized controlled trials (RCTs) and cluster RCTs conducted in hyperendemic and holoendemic malaria regions or that reported on any malaria‐related outcomes that included children younger than 18 years of age. We included trials that compared orally administered iron, iron with folic acid, and iron with antimalarial treatment versus placebo or no treatment. We included trials of iron supplementation or fortification interventions if they provided at least 80% of the Recommended Dietary Allowance (RDA) for prevention of anaemia by age. Antihelminthics could be administered to either group, and micronutrients had to be administered equally to both groups. DATA COLLECTION AND ANALYSIS: The primary outcomes were clinical malaria, severe malaria, and death from any cause. We assessed the risk of bias in included trials with domain‐based evaluation and assessed the quality of the evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach. We performed a fixed‐effect meta‐analysis for all outcomes and random‐effects meta‐analysis for hematological outcomes, and adjusted analyses for cluster RCTs. We based the subgroup analyses for anaemia at baseline, age, and malaria prevention or management services on trial‐level data. MAIN RESULTS: Thirty‐five trials (31,955 children) met the inclusion criteria. Overall, iron does not cause an excess of clinical malaria (risk ratio (RR) 0.93, 95% confidence intervals (CI) 0.87 to 1.00; 14 trials, 7168 children, high quality evidence). Iron probably does not cause an excess of clinical malaria in both populations where anaemia is common and those in which anaemia is uncommon. In areas where there are prevention and management services for malaria, iron (with or without folic acid) may reduce clinical malaria (RR 0.91, 95% CI 0.84 to 0.97; seven trials, 5586 participants, low quality evidence), while in areas where such services are unavailable, iron (with or without folic acid) may increase the incidence of malaria, although the lower CIs indicate no difference (RR 1.16, 95% CI 1.02 to 1.31; nine trials, 19,086 participants, low quality evidence). Iron supplementation does not cause an excess of severe malaria (RR 0.90, 95% CI 0.81 to 0.98; 6 trials, 3421 children, high quality evidence). We did not observe any differences for deaths (control event rate 1%, low quality evidence). Iron and antimalarial treatment reduced clinical malaria (RR 0.54, 95% CI 0.43 to 0.67; three trials, 728 children, high quality evidence). Overall, iron resulted in fewer anaemic children at follow up, and the end average change in haemoglobin from base line was higher with iron. AUTHORS' CONCLUSIONS: Iron treatment does not increase the risk of clinical malaria when regular malaria prevention or management services are provided. Where resources are limited, iron can be administered without screening for anaemia or for iron deficiency, as long as malaria prevention or management services are provided efficiently. 12 April 2019 No update planned Other There is high‐certainty evidence that oral iron supplements do not adversely affect children living in malaria‐endemic areas, meaning further research is unlikely to change our confidence in the estimate of effect. All eligible published studies found in the last search (30 Aug, 2015) were included. John Wiley & Sons, Ltd 2016-02-27 /pmc/articles/PMC4916933/ /pubmed/26921618 http://dx.doi.org/10.1002/14651858.CD006589.pub4 Text en Copyright © 2016 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane Collaboration. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the Creative Commons Attribution‐Non‐Commercial (https://creativecommons.org/licenses/by-nc/4.0/) Licence, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Neuberger, Ami
Okebe, Joseph
Yahav, Dafna
Paul, Mical
Oral iron supplements for children in malaria‐endemic areas
title Oral iron supplements for children in malaria‐endemic areas
title_full Oral iron supplements for children in malaria‐endemic areas
title_fullStr Oral iron supplements for children in malaria‐endemic areas
title_full_unstemmed Oral iron supplements for children in malaria‐endemic areas
title_short Oral iron supplements for children in malaria‐endemic areas
title_sort oral iron supplements for children in malaria‐endemic areas
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4916933/
https://www.ncbi.nlm.nih.gov/pubmed/26921618
http://dx.doi.org/10.1002/14651858.CD006589.pub4
work_keys_str_mv AT neubergerami oralironsupplementsforchildreninmalariaendemicareas
AT okebejoseph oralironsupplementsforchildreninmalariaendemicareas
AT yahavdafna oralironsupplementsforchildreninmalariaendemicareas
AT paulmical oralironsupplementsforchildreninmalariaendemicareas